Is Enanta Pharmaceuticals Stock a Good Investment?
Enanta Pharmaceuticals Investment Advice | ENTA |
- Examine Enanta Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Enanta Pharmaceuticals' leadership team and their track record. Good management can help Enanta Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Enanta Pharmaceuticals' business and its evolving consumer preferences.
- Compare Enanta Pharmaceuticals' performance and market position to its competitors. Analyze how Enanta Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Enanta Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Enanta Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Enanta Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Enanta Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Enanta Pharmaceuticals Stock
Researching Enanta Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enanta Pharmaceuticals has Price/Earnings (P/E) ratio of 366.13. The entity recorded a loss per share of 4.95. The firm had not issued any dividends in recent years.
To determine if Enanta Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enanta Pharmaceuticals' research are outlined below:
| Enanta Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 67.64 M. Net Loss for the year was (116.05 M) with profit before overhead, payroll, taxes, and interest of 66.59 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (78.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune Inflammatory Disease Virtual Conference |
Enanta Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enanta Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enanta Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Enanta Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Enanta Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-08-08 | 2016-06-30 | -0.09 | -0.06 | 0.03 | 33 | ||
2013-11-25 | 2013-09-30 | -0.29 | -0.25 | 0.04 | 13 | ||
2016-11-21 | 2016-09-30 | -0.14 | -0.09 | 0.05 | 35 | ||
2015-08-06 | 2015-06-30 | 0.19 | 0.13 | -0.06 | 31 | ||
2014-11-24 | 2014-09-30 | -0.33 | -0.27 | 0.06 | 18 | ||
2018-05-08 | 2018-03-31 | 0.53 | 0.61 | 0.08 | 15 | ||
2017-02-08 | 2016-12-31 | -0.18 | -0.26 | -0.08 | 44 | ||
2019-11-21 | 2019-09-30 | 0.53 | 0.44 | -0.09 | 16 |
Know Enanta Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enanta Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enanta Pharmaceuticals backward and forwards among themselves. Enanta Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Enanta Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2024-12-31 | 421.6 K | Northern Trust Corp | 2024-12-31 | 387.4 K | Stonepine Capital Management Llc | 2024-12-31 | 331.9 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 297.1 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 290 K | Assenagon Asset Management Sa | 2024-12-31 | 192.9 K | Caligan Partners Lp | 2024-12-31 | 184.8 K | Sio Capital Management, Llc | 2024-12-31 | 177 K | Jpmorgan Chase & Co | 2024-12-31 | 163.1 K | Krensavage Asset Management, Llc | 2024-12-31 | 2.1 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 2.1 M |
Enanta Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 125.44 M.Market Cap |
|
Enanta Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.34) | |
| Return On Capital Employed | (0.44) | (0.42) | |
| Return On Assets | (0.35) | (0.34) | |
| Return On Equity | (1.04) | (0.98) |
Determining Enanta Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Enanta Pharmaceuticals is a good buy. For example, gross profit margin measures Enanta Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enanta Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Enanta Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enanta Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enanta Pharmaceuticals' management manipulating its earnings.
Evaluate Enanta Pharmaceuticals' management efficiency
Enanta Pharmaceuticals has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.691) %, meaning that it created substantial loss on money invested by shareholders. Enanta Pharmaceuticals' management efficiency ratios could be used to measure how well Enanta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.34. The current year's Return On Capital Employed is expected to grow to -0.42. At present, Enanta Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 5.6 M, whereas Total Assets are forecasted to decline to about 333.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.48 | 5.91 | |
| Tangible Book Value Per Share | 5.48 | 5.93 | |
| Enterprise Value Over EBITDA | (2.61) | (2.48) | |
| Price Book Value Ratio | 1.53 | 1.88 | |
| Enterprise Value Multiple | (2.61) | (2.48) | |
| Price Fair Value | 1.53 | 1.88 | |
| Enterprise Value | 193.9 M | 203.6 M |
Understanding the operational decisions made by Enanta Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.481 |
Basic technical analysis of Enanta Stock
As of the 26th of March, Enanta Pharmaceuticals shows the Mean Deviation of 3.41, downside deviation of 3.44, and Semi Deviation of 3.31. Enanta Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Enanta Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enanta Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enanta Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enanta Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enanta Pharmaceuticals' Outstanding Corporate Bonds
Enanta Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enanta Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enanta bonds can be classified according to their maturity, which is the date when Enanta Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US29254BAA52 Corp BondUS29254BAA52 | View | |
| ENCANA P 65 Corp BondUS292505AD65 | View | |
| ENCANA P 6625 Corp BondUS292505AE49 | View | |
| ENCANA P 65 Corp BondUS292505AG96 | View | |
| OVV 515 15 NOV 41 Corp BondUS292505AK09 | View | |
| ENBRIDGE INC 45 Corp BondUS29250NAJ46 | View | |
| ENBRIDGE INC 425 Corp BondUS29250NAL91 | View | |
| ENBRIDGE INC 55 Corp BondUS29250NAM74 | View |
Understand Enanta Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Enanta Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.019 | |||
| Market Risk Adjusted Performance | 0.0579 | |||
| Mean Deviation | 3.41 | |||
| Semi Deviation | 3.31 | |||
| Downside Deviation | 3.44 | |||
| Coefficient Of Variation | 7960.41 | |||
| Standard Deviation | 5.35 | |||
| Variance | 28.65 | |||
| Information Ratio | 0.0102 | |||
| Jensen Alpha | 0.0539 | |||
| Total Risk Alpha | 0.0394 | |||
| Sortino Ratio | 0.0158 | |||
| Treynor Ratio | 0.0479 | |||
| Maximum Drawdown | 36.26 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 8.25 | |||
| Downside Variance | 11.86 | |||
| Semi Variance | 10.93 | |||
| Expected Short fall | (4.75) | |||
| Skewness | 2.62 | |||
| Kurtosis | 10.95 |
| Risk Adjusted Performance | 0.019 | |||
| Market Risk Adjusted Performance | 0.0579 | |||
| Mean Deviation | 3.41 | |||
| Semi Deviation | 3.31 | |||
| Downside Deviation | 3.44 | |||
| Coefficient Of Variation | 7960.41 | |||
| Standard Deviation | 5.35 | |||
| Variance | 28.65 | |||
| Information Ratio | 0.0102 | |||
| Jensen Alpha | 0.0539 | |||
| Total Risk Alpha | 0.0394 | |||
| Sortino Ratio | 0.0158 | |||
| Treynor Ratio | 0.0479 | |||
| Maximum Drawdown | 36.26 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 8.25 | |||
| Downside Variance | 11.86 | |||
| Semi Variance | 10.93 | |||
| Expected Short fall | (4.75) | |||
| Skewness | 2.62 | |||
| Kurtosis | 10.95 |
Consider Enanta Pharmaceuticals' intraday indicators
Enanta Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Enanta Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 10951.33 | |||
| Daily Balance Of Power | (0.78) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 6.05 | |||
| Day Typical Price | 5.99 | |||
| Price Action Indicator | (0.33) | |||
| Period Momentum Indicator | (0.32) | |||
| Relative Strength Index | 46.85 |
Enanta Pharmaceuticals Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 14th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 11th of February 2025 Other Reports | ViewVerify |
Enanta Stock media impact
Far too much social signal, news, headlines, and media speculation about Enanta Pharmaceuticals that are available to investors today. That information is available publicly through Enanta media outlets and privately through word of mouth or via Enanta internal channels. However, regardless of the origin, that massive amount of Enanta data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Enanta Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Enanta Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Enanta Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Enanta Pharmaceuticals alpha.
Enanta Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Enanta Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Enanta Pharmaceuticals Corporate Management
| Nathaniel JD | General VP | Profile | |
| Scott MD | Senior Officer | Profile | |
| Nathalie MD | Consultant | Profile | |
| Jennifer Viera | Executive Communications | Profile | |
| Tara Kieffer | Senior Development | Profile | |
| Brendan Luu | Senior Development | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (4.95) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Enanta Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.